The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload

A L Sverdlov; D T M Ngo; A K Nightingale; S Rajendran; K Mishra; T Heresztyn; R H Ritchie; T H Marwick; M P Frenneaux; J D Horowitz

doi:10.1016/j.niox.2011.04.009

The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload

A L Sverdlov, D T M Ngo, A K Nightingale, S Rajendran, K Mishra, T Heresztyn, R H Ritchie, T H Marwick, M P Frenneaux, J D Horowitz

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

Nitric oxide (NO) is a modulator of left ventricular hypertrophy (LVH) and myocardial relaxation. The impact of NO availability on development of LVH has never been demonstrated in humans. We tested the hypotheses that elevation of asymmetric dimethylarginine (ADMA) concentrations (biochemical marker of decreased NO generation), and impairment of vascular responsiveness to NO donor GTN, would each predict the presence of LVH and associated LV diastolic dysfunction in a normal aging population.

Original language	English
Pages (from-to)	41-46
Number of pages	6
Journal	Nitric Oxide: Biology and Chemistry
Volume	25
Issue number	1
DOIs	https://doi.org/10.1016/j.niox.2011.04.009
Publication status	Published - 30 Jun 2011

Keywords

left ventricular mass
nitric oxide
vascular function
diastolic function
asymmetric dimethylarginine

Access to Document

10.1016/j.niox.2011.04.009

Cite this

Sverdlov, A. L., Ngo, D. T. M., Nightingale, A. K., Rajendran, S., Mishra, K., Heresztyn, T., Ritchie, R. H., Marwick, T. H., Frenneaux, M. P., & Horowitz, J. D. (2011). The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload. Nitric Oxide: Biology and Chemistry, 25(1), 41-46. https://doi.org/10.1016/j.niox.2011.04.009

The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload. / Sverdlov, A L; Ngo, D T M; Nightingale, A K; Rajendran, S; Mishra, K; Heresztyn, T; Ritchie, R H; Marwick, T H; Frenneaux, M P; Horowitz, J D.

In: Nitric Oxide: Biology and Chemistry, Vol. 25, No. 1, 30.06.2011, p. 41-46.

Research output: Contribution to journal › Article › peer-review

@article{b3da47ebc0fb4155a01912b60aa4c48b,

title = "The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload",

abstract = "Nitric oxide (NO) is a modulator of left ventricular hypertrophy (LVH) and myocardial relaxation. The impact of NO availability on development of LVH has never been demonstrated in humans. We tested the hypotheses that elevation of asymmetric dimethylarginine (ADMA) concentrations (biochemical marker of decreased NO generation), and impairment of vascular responsiveness to NO donor GTN, would each predict the presence of LVH and associated LV diastolic dysfunction in a normal aging population.",

keywords = "left ventricular mass, nitric oxide, vascular function, diastolic function, asymmetric dimethylarginine",

author = "Sverdlov, {A L} and Ngo, {D T M} and Nightingale, {A K} and S Rajendran and K Mishra and T Heresztyn and Ritchie, {R H} and Marwick, {T H} and Frenneaux, {M P} and Horowitz, {J D}",

note = "Copyright {\textcopyright} 2011. Published by Elsevier Inc.",

year = "2011",

month = jun,

day = "30",

doi = "10.1016/j.niox.2011.04.009",

language = "English",

volume = "25",

pages = "41--46",

journal = "Nitric Oxide: Biology and Chemistry",

issn = "1089-8603",

publisher = "Academic Press Inc.",

number = "1",

}

TY - JOUR

T1 - The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload

AU - Sverdlov, A L

AU - Ngo, D T M

AU - Nightingale, A K

AU - Rajendran, S

AU - Mishra, K

AU - Heresztyn, T

AU - Ritchie, R H

AU - Marwick, T H

AU - Frenneaux, M P

AU - Horowitz, J D

PY - 2011/6/30

Y1 - 2011/6/30

N2 - Nitric oxide (NO) is a modulator of left ventricular hypertrophy (LVH) and myocardial relaxation. The impact of NO availability on development of LVH has never been demonstrated in humans. We tested the hypotheses that elevation of asymmetric dimethylarginine (ADMA) concentrations (biochemical marker of decreased NO generation), and impairment of vascular responsiveness to NO donor GTN, would each predict the presence of LVH and associated LV diastolic dysfunction in a normal aging population.

AB - Nitric oxide (NO) is a modulator of left ventricular hypertrophy (LVH) and myocardial relaxation. The impact of NO availability on development of LVH has never been demonstrated in humans. We tested the hypotheses that elevation of asymmetric dimethylarginine (ADMA) concentrations (biochemical marker of decreased NO generation), and impairment of vascular responsiveness to NO donor GTN, would each predict the presence of LVH and associated LV diastolic dysfunction in a normal aging population.

KW - left ventricular mass

KW - nitric oxide

KW - vascular function

KW - diastolic function

KW - asymmetric dimethylarginine

U2 - 10.1016/j.niox.2011.04.009

DO - 10.1016/j.niox.2011.04.009

M3 - Article

C2 - 21550414

VL - 25

SP - 41

EP - 46

JO - Nitric Oxide: Biology and Chemistry

JF - Nitric Oxide: Biology and Chemistry

SN - 1089-8603

IS - 1

ER -

The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload

Abstract

Keywords

Access to Document

Fingerprint

Cite this